956 related articles for article (PubMed ID: 26436649)
1. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
2. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
3. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
4. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
Anthony RM; Ravetch JV
J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
[TBL] [Abstract][Full Text] [Related]
7. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
8. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
9. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
Mimura Y; Kelly RM; Unwin L; Albrecht S; Jefferis R; Goodall M; Mizukami Y; Mimura-Kimura Y; Matsumoto T; Ueoka H; Rudd PM
J Immunol Methods; 2016 Jan; 428():30-6. PubMed ID: 26627984
[TBL] [Abstract][Full Text] [Related]
10. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
11. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
12. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
13. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
[TBL] [Abstract][Full Text] [Related]
14. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
17. Engineering IgG1 Fc Domains That Activate the Complement System.
Lee CH; Delidakis G
Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
[TBL] [Abstract][Full Text] [Related]
18. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
19. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
[TBL] [Abstract][Full Text] [Related]
20. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.
Wong AH; Fukami Y; Sudo M; Kokubun N; Hamada S; Yuki N
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):275-9. PubMed ID: 25814494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]